BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28972794)

  • 1. Can sparing of the superficial contralateral parotid lobe reduce xerostomia following radiotherapy for head and neck cancer?
    Nevens D; Nuyts S
    Br J Radiol; 2017 Dec; 90(1080):20170596. PubMed ID: 28972794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
    Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
    Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parotid gland sparing in patients undergoing bilateral head and neck irradiation: techniques and early results.
    Eisbruch A; Ship JA; Martel MK; Ten Haken RK; Marsh LH; Wolf GT; Esclamado RM; Bradford CR; Terrell JE; Gebarski SS; Lichter AS
    Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):469-80. PubMed ID: 8892473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
    Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
    Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
    Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model for predicting the dose to the parotid glands based on their relative overlapping with planning target volumes during helical radiotherapy.
    Millunchick CH; Zhen H; Redler G; Liao Y; Turian JV
    J Appl Clin Med Phys; 2018 Mar; 19(2):48-53. PubMed ID: 29105949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes.
    Tam M; Riaz N; Kannarunimit D; Peña AP; Schupak KD; Gelblum DY; Wolden SL; Rao S; Lee NY
    Am J Clin Oncol; 2015 Aug; 38(4):343-7. PubMed ID: 26208401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy.
    Henson BS; Inglehart MR; Eisbruch A; Ship JA
    Oral Oncol; 2001 Jan; 37(1):84-93. PubMed ID: 11120488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer.
    Eisbruch A; Kim HM; Terrell JE; Marsh LH; Dawson LA; Ship JA
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):695-704. PubMed ID: 11395238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique.
    Amosson CM; Teh BS; Van TJ; Uy N; Huang E; Mai WY; Frolov A; Woo SY; Chiu JK; Carpenter LS; Lu HH; Grant WH; Butler EB
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):136-44. PubMed ID: 12694832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer.
    Bussels B; Maes A; Hermans R; Nuyts S; Weltens C; Van den Bogaert W
    Radiother Oncol; 2004 Aug; 72(2):119-27. PubMed ID: 15297131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study.
    Burlage FR; Roesink JM; Kampinga HH; Coppes RP; Terhaard C; Langendijk JA; van Luijk P; Stokman MA; Vissink A
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):14-22. PubMed ID: 17869018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parotid-gland-sparing 3D conformal radiotherapy in patients with bilateral radiotherapy of the head and neck region--results in clinical practice.
    Hey J; Setz J; Gerlach R; Janich M; Sehlleier S; Schaller HG; Gernhardt CR; Kuhnt T
    Oral Oncol; 2009 Feb; 45(2):e11-7. PubMed ID: 18621572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands.
    Little M; Schipper M; Feng FY; Vineberg K; Cornwall C; Murdoch-Kinch CA; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):1007-14. PubMed ID: 22056067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
    van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preservation of parotid function with uncomplicated conformal radiotherapy.
    Maes A; Weltens C; Flamen P; Lambin P; Bogaerts R; Liu X; Baetens J; Hermans R; Van den Bogaert W
    Radiother Oncol; 2002 May; 63(2):203-11. PubMed ID: 12063010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parotid gland mean dose as a xerostomia predictor in low-dose domains.
    Gabryś HS; Buettner F; Sterzing F; Hauswald H; Bangert M
    Acta Oncol; 2017 Sep; 56(9):1197-1203. PubMed ID: 28502238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting acute radiation induced xerostomia in head and neck Cancer using MR and CT Radiomics of parotid and submandibular glands.
    Sheikh K; Lee SH; Cheng Z; Lakshminarayanan P; Peng L; Han P; McNutt TR; Quon H; Lee J
    Radiat Oncol; 2019 Jul; 14(1):131. PubMed ID: 31358029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.